Pacira BioSciences’ (PCRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Pacira BioSciences (NASDAQ:PCRX) in a research note published on Wednesday,Benzinga reports. They currently have a $39.00 price objective on the stock.

PCRX has been the topic of several other reports. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a report on Friday, November 8th. Jefferies Financial Group increased their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. StockNews.com cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. reissued an “underweight” rating and set a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Finally, Royal Bank of Canada upped their price objective on Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Stock Up 3.2 %

PCRX stock opened at $19.27 on Wednesday. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The firm has a 50 day moving average price of $16.86 and a 200-day moving average price of $19.48. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $35.95.

Hedge Funds Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently modified their holdings of PCRX. GAMMA Investing LLC grew its holdings in shares of Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after acquiring an additional 932 shares during the period. Outfitter Financial LLC grew its stake in shares of Pacira BioSciences by 5.7% during the 2nd quarter. Outfitter Financial LLC now owns 20,190 shares of the company’s stock valued at $578,000 after purchasing an additional 1,095 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Pacira BioSciences by 6.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company’s stock valued at $685,000 after purchasing an additional 1,354 shares during the last quarter. nVerses Capital LLC lifted its stake in shares of Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares during the period. Finally, Innealta Capital LLC purchased a new position in shares of Pacira BioSciences in the second quarter worth approximately $50,000. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.